1. Home
  2. TRNR vs ARTL Comparison

TRNR vs ARTL Comparison

Compare TRNR & ARTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Interactive Strength Inc.

TRNR

Interactive Strength Inc.

N/A

Current Price

$1.76

Market Cap

2.8M

Sector

Technology

ML Signal

N/A

ARTL

Artelo Biosciences Inc.

HOLD

Current Price

$2.66

Market Cap

2.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TRNR
ARTL
Founded
2017
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Consumer Electronics/Appliances
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.8M
2.5M
IPO Year
2023
2014

Fundamental Metrics

Financial Performance
Metric
TRNR
ARTL
Price
$1.76
$2.66
Analyst Decision
Buy
Analyst Count
2
0
Target Price
★ $10.00
N/A
AVG Volume (30 Days)
31.7K
★ 1.2M
Earning Date
11-16-2026
11-11-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
N/A
★ N/A
Revenue
★ $11,530,000.00
N/A
Revenue This Year
$117.64
N/A
Revenue Next Year
$10.59
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ 114.31
N/A
52 Week Low
$1.70
$0.52
52 Week High
$3,378.70
$179.19

Technical Indicators

Market Signals
Indicator
TRNR
ARTL
Relative Strength Index (RSI) 24.04 34.20
Support Level N/A $0.52
Resistance Level $3.23 $6.81
Average True Range (ATR) 0.12 0.19
MACD 0.23 -0.01
Stochastic Oscillator 14.08 0.00

Price Performance

Historical Comparison
TRNR
ARTL

About TRNR Interactive Strength Inc.

Interactive Strength Inc provides an integrated home fitness platform that allows its customers to participate in interactive wellness and strength-based training sessions. Its health coaching services encompass guidance and coaching on nutrition, recovery, sleep, and other health and lifestyle categories. The company generates revenue from sales of its connected fitness products, membership revenue, and personal training revenue.

About ARTL Artelo Biosciences Inc.

Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.

Share on Social Networks: